| Literature DB >> 35173527 |
Shafiu A Umar Shinge1, Daifang Zhang1,2, Ahmad Ud Din3, FengXu Yu1,4, YongMei Nie1,4.
Abstract
Purpose of Review: Atherosclerosis is the principal cause of cardiovascular diseases (CVDs) which are the major cause of death worldwide. Mechanical force plays an essential role in cardiovascular health and disease. To bring the awareness of mechanosensitive Piezo1 role in atherosclerosis and its therapeutic potentials we review recent literature to highlight its involvement in various mechanisms of the disease. Recent Findings: Recent studies reported Piezo1 channel as a sensor, and transducer of various mechanical forces into biochemical signals, which affect various cellular activities such as proliferation, migration, apoptosis and vascular remodeling including immune/inflammatory mechanisms fundamental phenomenon in atherogenesis. Summary: Numerous evidences suggest Piezo1 as a player in different mechanisms of cell biology, including immune/inflammatory and other cellular mechanisms correlated with atherosclerosis. This review discusses mechanistic insight about this matter and highlights the drugability and therapeutic potentials consistent with emerging functions Piezo1 in various mechanisms of atherosclerosis. Based on the recent works, we suggest Piezo1 as potential therapeutic target and a valid candidate for future research. Therefore, a deeper exploration of Piezo1 biology and translation towards the clinic will be a novel strategy for treating atherosclerosis and other CVDs. © The author(s).Entities:
Keywords: Atherosclerosis; Endothelial cell; Inflammation; Piezo1 channel; mechanomedicine; shear stress
Mesh:
Substances:
Year: 2022 PMID: 35173527 PMCID: PMC8771847 DOI: 10.7150/ijbs.63819
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 6.580
Demonstrated activation and inactivation sites of Piezo1
| Mechanical | Chemical | ||
|---|---|---|---|
| Activation | Inactivation | Activation | Inactivation |
|
| |||
| N-terminal proximity 86 &300 sites | External pore domain sites 2,422 & 2,425 | EL15- 16, EL19-20 & L1342/L1345 at the beam | L2475 & V2476 Residues |
Summarization of current Piezo1 pharmacology
| Agents | Binding site (domain) | References | |
|---|---|---|---|
|
| |||
|
| Yoda | C-terminal (ATM area) | |
| Jedi1/2 | L15-16/L19-20 area | ||
|
| |||
|
| |||
|
| Unsaturated-Docosahexaenoic acid | Slow inactivation |
|
| Saturated-Margaric acid | Speedup inactivation | ||
|
| |||
|
| GsMTx4 | Pore of the channel | |
| Ruthenium Red | |||
| gadolinium | |||
|
| Tubeimoside1 | Compete with Yoda1 | |
| Dooku1 | |||
Summarizing the cardiovascular and immune functions of Piezo1
| Organ/Tissue | Functions | Associated disorder | Human/animal; mutation/genetic disruption, inhibition or Up-regulation/Downregulation | Cell type | Interactions | Downstream mechanisms | References |
|---|---|---|---|---|---|---|---|
| Heart | Ventricular remodeling | Heart failure | Human; upregulation | Cardiomyocytes | Hemodynamic/mechanical force, shear stress, | AngII dependent deterioration of failing heart |
|
| Ca | Cardiomyopathy | mKO | Cardiomyocytes | Hemodynamic/mechanical force, shear stress | Cardiac Ca |
| |
| Opposing cardiac fibroblast myo-differentiating | NR | NE | Cardiac fibroblast | Pressure | IL-6 secreting |
| |
| Blood/Lymph Vessels | Hypertension-dependent remodeling of artery, BP regulation, Ca2+ influx & ECM degradation in AAA | Arterial remodeling, | mcKO | SMCs | Hemodynamic force, shear stress, mechanical stretching | Rise in transglutaminase 2 activities | |
| Brain vascular pathfinding, vascular growth, vessel tone & remodeling, Control of placental blood flow, EC migration; Vessel architecture; Hyperpermeability of Pulmonary micro vessels | Atherosclerosis, | mcKO, Upregulation/dowmregulation | VECs | Hemodynamic force, shear stress, | Trigger of eNOS, AKT, KLF2, VEGFR2 & tyrosine phosphorylating, P2Y2 (purinergic receptor type 2Y2) receptor activation | ||
| Lymphatic valves development & sustenance | Generalized lymphatic dysplasia | mcKO (LFm humans) | LECs | Hemodynamic force, shear stress, cyclic stretch | actomyosin & VE-cadherin remodeling | ||
| RBC Volume regulation, release of ATP | DHS and Plasmodium infection, Hemolytic anemia | GFm humans, cKd | RBC | Hemodynamic force, shear stress | Elevated cation permeability leading to dehydrating of erythrocyte | ||
| Shear-evoked influx of Ca2+, Platelet activation & thrombogenesis | NR | NE | Platelets | Shear stress | Not clear | ||
| Baroreceptor reflex | Baroreflex dysfunctioning | mKO/mutant Piezo1&2 | nodose & petrosa | Hemodynamic force, shear stress, | Raise in mean arterial pressure | ||
| Immune system | Prevent against P.aeruginosa, generation of EDN1 and HIF1α | Dysfunctional immunity against P. aeruginosa | mcKO/ inhibition | Monocyte/Macrophage | Cyclic pressure | Neutrophil recruiting and clearing of pathogens | |
| Influx of Ca2+ and TCR stimulation | Unknown | Downregulation/inhibition | T-cells | Mechanical force/ | Calpain trigger, actin scaffold reorganizing, and stabilizing immunological synapse |
Abbreviations: TCR; T cell antigen receptor, GLD; generalized lymphatic dysplasia, ECM; extracellular matrix, mcKO; mice conditional knockout, NE; not explored, BP; blood pressure; DHS; dehydrated hereditary stomatocytosis; GFm, gain-of-function mutant, cKd; conditional knockdown, NR; not reported, AAA; Abdominal aortic aneurysm.
Figure 1Cardiovascular expression and function of Piezo1, the detail Piezo1 role in each cell and tissue shown here explains in the main text of the review. In the diagram I-VI illustrating the significant functions of Piezo1 in EC, SMC, RBC, cardiomyocyte, cardiac fibroblast and vasculature.
Figure 2The diagram displays expressions and functions of Piezo1 in immune cells, comprising monocyte, macrophage and T-cells, illustrating the activities of these cell and secretion of chemokines after Piezo1 dependent activation as discussed in the main text of this work.
Figure 3The diagram illustrates the atherogenic role of Piezo1 in different mechanical signals; first segment (vessel lumen) initiating Piezo1 dependent Ca2+ entry and trigger of atheroprotective signaling through EC activation and regulation of gene expression KLF2, NO and maintaining noninflammatory, non-proliferative/migrative quiescent EC. Second segment turbulent/oscillatory flow (red arrow) Piezo1 dependent triggering of proatherosclerotic signaling via EC activation to proinflammatory phenotype and immune/inflammatory cell recruitment, proinflammatory gene expression NF-κB, cytokine release (VCAM-1 ICAM-1) and result in cell proliferation and migration, leading to macrophage accumulation and form cell formation and atherosclerosis development. In addition to second segment, third segment distension/circumferential stretches (blue arrow) Piezo1 dependent stretch stimulation leading to trans-differentiation of EC to SMC phenotype, and SMC into macrophages, proliferation migration and apoptosis, release of growth factors TGFβ and cytokines TNFα, IL-6, IL1β, MCP-1 etc, contributing to disease progression and plague rupture. Fourth segment advanced atherosclerotic plaque and thrombus formation.
Figure 4The diagram depicted Piezo1 dependent signaling; (left) inflammatory mechanism of AS by disturbed/oscillatory shear leading to the release of cytokines and adhesion molecule, inflammatory cell recruitment, EC dysfunction and inflammation, facilitating the development of AS, (middle) Piezo1 dependent activation of immune cells by cyclic pressure result in cytokine release, proliferation migration form cell formation and disease development, (left)Piezo1 dependent stretch activation of EC and SMC leading to changes in gene expression and growth factor secretion and result in proliferation and migration facilitating the development of atherosclerosis.